Neuralstem Updates ALS Clinical Trial Progress

The first FDA approved stem cell clinical trial for ALS is reported to be on track. Neuralstem has completed safety evaluations of its first cohort of ALS patients and plans to move forward with the second cohort using a more extensive treatment regime.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail